Phosphodiesterase 4 inhibition as a novel treatment for stroke

Jiahong Zhong, Xin Yu, Zhuomiao LinPeerJ 2025 · DOI

TL;DR

This review explores phosphodiesterase 4 (PDE4) inhibition as a promising novel therapeutic strategy for stroke. By targeting PDE4, researchers aim to enhance neural plasticity, regulate cellular metabolism, and reduce secondary brain injury, offering a new avenue beyond current limited treatments.

What Problem Does This Paper Address?

Stroke is a leading cause of death and disability worldwide, characterized by high morbidity, disability, and recurrence rates. Current treatments, like thrombolytic drugs, are effective but have limitations due to their time-sensitive nature and risk of bleeding. Surgical interventions also carry significant risks. The paper highlights the urgent need for effective neuroprotective drugs that can enhance neurological function and mitigate brain damage following ischemic events. Specifically, it addresses the limitations of existing treatments and the potential of targeting the PDE4 pathway, which has shown a correlation with ischemic stroke risk.

Methods

This paper is a comprehensive literature review and scientometric analysis. The authors conducted a literature search on "phosphodiesterase 4" and "stroke" using PubMed and Google Scholar, focusing on articles published between 1994 and 2024. They employed Boolean operators to refine their search and excluded grey literature and review articles. The review synthesizes existing research on the pathophysiology of stroke, the structure and function of PDE4, the relationship between PDE4D gene polymorphisms and stroke risk, and the therapeutic potential of PDE4 inhibitors.

Datasets

Not discussed in the paper. This is a literature review.

Key Insights and Ideas

  • PDE4 as a Therapeutic Target: The PDE4 enzyme family plays a crucial role in regulating intracellular cyclic adenosine monophosphate (cAMP) levels, which are critical for various cellular processes, including neuronal function and survival. Inhibiting PDE4 can increase cAMP, leading to beneficial effects in stroke.
  • Mechanism of Action: PDE4 inhibitors can enhance synaptic plasticity, improve neuronal metabolism, and protect against secondary brain injury by reducing inflammation, attenuating the cAMP signaling cascade, promoting synaptic remodeling, and stimulating angiogenesis.
  • PDE4D Gene Polymorphism: Studies suggest a positive correlation between variations in the PDE4D gene and an increased risk of ischemic stroke, indicating a genetic predisposition that could be targeted.
  • Beyond Thrombolysis: While thrombolytic drugs are the current standard for acute ischemic stroke, their limitations necessitate the development of neuroprotective agents. PDE4 inhibitors offer a promising alternative or complementary approach.
  • Challenges in PDE4 Inhibition: Developing selective PDE4 inhibitors is challenging due to the high homology among PDE4 subtypes. Gastrointestinal side effects (nausea, vomiting) have been a significant hurdle for earlier generations of PDE4 inhibitors.

Key Results

The review synthesizes findings from numerous studies, indicating that:

  • Neuroprotection: PDE4 inhibitors have demonstrated neuroprotective effects in various experimental models of stroke by reducing inflammation, apoptosis, and oxidative stress.
  • Functional Recovery: These inhibitors have shown potential in improving synaptic plasticity, learning, and memory, which are crucial for functional recovery after stroke.
  • Angiogenesis and Remodeling: PDE4 inhibition can promote angiogenesis and synaptic remodeling, contributing to the repair and recovery of brain tissue.
  • Gene Association: Genetic studies have linked PDE4D gene polymorphisms to an increased risk of ischemic stroke, suggesting a role for this pathway in stroke susceptibility.
  • Drug Development: While first-generation PDE4 inhibitors faced significant side effects, newer generations and strategies like tissue-selective delivery are being explored to improve safety and efficacy.

Limitations and Future Work

The authors acknowledge several limitations and suggest future directions:

  • Subtype Selectivity: Achieving subtype-specific PDE4 inhibition remains a challenge, and further research is needed to develop inhibitors that selectively target specific PDE4 isoforms to minimize off-target effects, particularly gastrointestinal side effects.
  • Blood-Brain Barrier Permeability: Enhancing the blood-brain barrier permeability of PDE4 inhibitors is crucial for effective delivery to the brain and achieving therapeutic concentrations.
  • Clinical Translation: While preclinical data is promising, more extensive clinical trials are needed to confirm the safety and efficacy of PDE4 inhibitors in human stroke patients.
  • Mechanism Elucidation: Further research is required to fully elucidate the complex mechanisms by which PDE4 inhibition exerts its protective effects in stroke, including its interactions with various signaling pathways and neurotrophic factors.
  • Personalized Medicine: Exploring personalized approaches based on PDE4D gene polymorphisms and individual patient characteristics could optimize treatment strategies.

Summary updated

Abstract

The incidence of stroke ranks third among the leading causes of mortality worldwide. It has the characteristics of high morbidity, high disability rate and high recurrence rate. The current risk associated with stroke surgery is exceedingly high. It may potentially outweigh the benefits and fail to ameliorate the cerebral tissue damage following ischemia. Therefore, pharmacological intervention assumes paramount importance. The use of thrombolytic drugs is most common in the treatment of stroke; however, its efficacy is limited due to its time-sensitive nature and propensity for increased bleeding. Over the past few years, the treatment of stroke has witnessed a surge in interest towards neuroprotective drugs that possess the potential to enhance neurological function. The PDE4D gene has been demonstrated to have a positive correlation with the risk of ischemic stroke. Additionally, the utilization of phosphodiesterase 4 inhibitors can enhance synaptic plasticity within the neural circuitry, regulate cellular metabolism, and prevent secondary brain injury caused by impaired blood flow. These mechanisms collectively facilitate the recovery of functional neurons, thereby serving as potential therapeutic interventions. Therefore, the comprehensive investigation of phosphodiesterase 4 as an innovative pharmacological target for stroke injury provides valuable insights into the development of therapeutic interventions in stroke treatment. This review is intended for, but not limited to, pharmacological researchers, drug target researchers, neurologists, neuromedical researchers, and behavioral scientists.
BibTeX
@inproceedings{zhong2025phosphodiesterase,
  author = {Jiahong Zhong and Xin Yu and Zhuomiao Lin},
  title = {{Phosphodiesterase 4 inhibition as a novel treatment for stroke}},
  booktitle = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.18905},
}
Figure